Wal-Mart Financial Technology Company is valued at $2.5 billion, and retailers inject a lot of cash.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)Zhongzhiwei Technology completed tens of millions of yuan financing. On December 12th, Nanjing Zhongzhiwei Information Technology Co., Ltd. (Zhongzhiwei Technology) completed tens of millions of yuan B1 financing, which was jointly invested by Guangzhou Baiyun Financial Holding Group Co., Ltd. and Beijing Hongfeng Private Equity Fund Management Co., Ltd. This round of financing funds will be used for iterative application of AI+ network security products, breakthrough in key industry landing scenarios and market channel construction. Zhongzhiwei Technology is a solution provider of "city-level data+digital security operation", and has launched a series of new platform-based network security products around AISecOps (artificial intelligence security operation).
Real estate stocks are active again and again. Huayuan Real Estate and Qixia Construction both have daily limit, while Huayuan Real Estate, Qixia Construction, Xinhualian and Xinhuangpu have daily limit, while Suzhou Gaoxin, China Wuyi and Shahe shares have followed suit.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)European Central Bank: It is estimated that the GDP growth rate will be 0.7% in 2024, 1.1% in 2025, 1.4% in 2026 and 1.3% in 2027. (It is expected to be 0.8%, 1.3% and 1.5% respectively in September) It is estimated that the core inflation rate will be 2.9% in 2024, 2.3% in 2025 and 1.9% in 2026. (It is expected to be 2.8%, 2.3% and 2.0% respectively in September) It is estimated that the core inflation rate will be 1.9% in 2027.
Russian central bank: Russia's current account surplus in November was $3.2 billion.Korean media: The director of the South Korean Police Department who was arrested in an emergency for "civil strife" was sent to the hospital due to the deterioration of his health. According to Yonhap News Agency's latest news from the police on the 12th, Zhao Zhihao, the director of the South Korean Police Department who was arrested in an emergency on suspicion of "civil strife" in the early morning of the 11th, has been sent to the hospital for treatment due to the deterioration of his health. (World Wide Web)Enterprise IT Expenditure Survey: Google Cloud is expected to be the first choice for 50% of the respondents. Tae Kim, a science and technology columnist, wrote that according to a recent survey, Google Cloud has risen rapidly in the enterprise AI expenditure competition and may become the winner. According to the 2025 CIO survey released by Piper Sandler, 81 CIOs were asked about their budget priorities in different suppliers and technical fields. According to the survey, 87% of CIOs surveyed expect to increase the IT budget in 2025, which is the highest proportion of the survey since 2020. In this survey, the status of Google Cloud has risen significantly, surpassing Microsoft and OpenAI to become the "most strategic" AI supplier, with a support rate of 27%, a significant increase from 15% six months ago. Relatively speaking, Microsoft's support rate dropped from 33% to 24%. When asked which cloud company they plan to use to test or implement AI projects next year, 50% of the respondents chose Google Cloud, making it the top AI infrastructure provider. In addition, Harsh Kumar, a Piper semiconductor analyst, pointed out that these results are also beneficial to Invista, because all cloud companies are the main buyers of AI chips in NVIDIA. Kumar estimates that the entire AI chip market will have more than $500 billion in business opportunities by 2028.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
Strategy guide 12-14